COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03%
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Additional Paid In Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Additional Paid In Capital
$4.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Additional Paid In Capital
$28.4m
CAGR 3-Years
24%
CAGR 5-Years
20%
CAGR 10-Years
16%
Repare Therapeutics Inc
NASDAQ:RPTX
Additional Paid In Capital
$85.9m
CAGR 3-Years
39%
CAGR 5-Years
77%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Additional Paid In Capital
$109.9m
CAGR 3-Years
12%
CAGR 5-Years
26%
CAGR 10-Years
22%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Additional Paid In Capital
$223.8m
CAGR 3-Years
18%
CAGR 5-Years
39%
CAGR 10-Years
21%
Spectral Medical Inc
TSX:EDT
Additional Paid In Capital
CA$10.1m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
3%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Additional Paid In Capital?
Additional Paid In Capital
4.2m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Additional Paid In Capital amounts to 4.2m USD.

What is COSCIENS Biopharma Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 1Y
-4%

Over the last year, the Additional Paid In Capital growth was -4%.

Back to Top